drugset / Trial / NCT06378138
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Timeline
- Start
- 2024-05-15
- Primary completion
- 2030-11-25
- Completion
- 2031-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-248 | Unknown | — | Oral |
| Background | Orelabrutinib | Small molecule | — | Oral |